On Monday, Bolt Biotherapeutics Inc (NASDAQ: BOLT) was -1.88% drop from the session before settling in for the closing price of $0.53. A 52-week range for BOLT has been $0.51 – $1.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 169.01% over the past five years. When this article was written, the company’s average yearly earnings per share was at 15.48%. With a float of $25.82 million, this company’s outstanding shares have now reached $38.27 million.
Let’s look at the performance matrix of the company that is accounted for 100 employees. In terms of profitability, gross margin is -67.58%, operating margin of -776.13%, and the pretax margin is -665.56%.
Bolt Biotherapeutics Inc (BOLT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bolt Biotherapeutics Inc stocks. The insider ownership of Bolt Biotherapeutics Inc is 32.53%, while institutional ownership is 21.95%.
Bolt Biotherapeutics Inc (BOLT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.48% per share during the next fiscal year.
Bolt Biotherapeutics Inc (NASDAQ: BOLT) Trading Performance Indicators
You can see what Bolt Biotherapeutics Inc (BOLT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Bolt Biotherapeutics Inc (BOLT)
Bolt Biotherapeutics Inc (NASDAQ: BOLT) saw its 5-day average volume 0.25 million, a positive change from its year-to-date volume of 0.17 million. As of the previous 9 days, the stock’s Stochastic %D was 9.82%. Additionally, its Average True Range was 0.04.
During the past 100 days, Bolt Biotherapeutics Inc’s (BOLT) raw stochastic average was set at 5.52%, which indicates a significant decrease from 10.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.90% in the past 14 days, which was higher than the 39.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6182, while its 200-day Moving Average is $0.8139. Nevertheless, the first resistance level for the watch stands at $0.5311 in the near term. At $0.5442, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5584. If the price goes on to break the first support level at $0.5038, it is likely to go to the next support level at $0.4896. The third support level lies at $0.4765 if the price breaches the second support level.
Bolt Biotherapeutics Inc (NASDAQ: BOLT) Key Stats
There are 38,273K outstanding shares of the company, which has a market capitalization of 19.83 million. As of now, sales total 7,880 K while income totals -69,200 K. Its latest quarter income was 1,140 K while its last quarter net income were -15,180 K.
